US 11,912,659 B2
EBNA1 inhibitors and methods using same
Troy E. Messick, Upper Darby, PA (US); Garry R. Smith, King of Prussia, PA (US); Allen B. Reitz, Lansdale, PA (US); Paul M. Lieberman, Wynnewood, PA (US); Mark E. McDonnell, Lansdale, PA (US); Yan Zhang, Fort Washington, PA (US); Marianne Carlsen, Yardley, PA (US); and Shuai Chen, Philadelphia, PA (US)
Assigned to The Wistar Institute of Anatomy and Biology, Philadelphia, PA (US)
Filed by The Wistar Institute of Anatomy and Biology, Philadelphia, PA (US)
Filed on Apr. 16, 2021, as Appl. No. 17/232,511.
Application 16/571,896 is a division of application No. 15/571,223, granted, now 10,442,763, issued on Oct. 15, 2019, previously published as PCT/US2016/032574, filed on May 14, 2016.
Application 17/232,511 is a continuation of application No. 16/571,896, filed on Sep. 16, 2019, granted, now 10,981,867.
Claims priority of provisional application 62/161,490, filed on May 14, 2015.
Prior Publication US 2022/0064112 A1, Mar. 3, 2022
Int. Cl. C07D 209/08 (2006.01); C07D 403/12 (2006.01); C07D 405/14 (2006.01); C07D 401/12 (2006.01); C07D 405/12 (2006.01); C07D 409/12 (2006.01); C07D 487/08 (2006.01); C07D 471/08 (2006.01); C07D 417/12 (2006.01); A61P 35/00 (2006.01); A61P 31/20 (2006.01); A61K 31/404 (2006.01); A61K 31/41 (2006.01); A61K 31/4155 (2006.01); A61K 31/422 (2006.01); A61K 31/426 (2006.01); A61K 31/427 (2006.01); A61K 31/433 (2006.01); A61K 31/435 (2006.01); A61K 31/437 (2006.01); A61K 31/4375 (2006.01); A61K 31/4439 (2006.01); A61K 31/454 (2006.01); A61K 31/4725 (2006.01); A61K 31/496 (2006.01); A61K 31/501 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); A61K 31/519 (2006.01); A61K 31/5377 (2006.01); A61K 31/541 (2006.01); A61K 31/551 (2006.01); A61K 45/06 (2006.01); C07D 277/62 (2006.01); C07D 401/10 (2006.01); C07D 401/14 (2006.01); C07D 403/10 (2006.01); C07D 403/14 (2006.01); C07D 413/10 (2006.01); C07D 417/10 (2006.01); C07D 471/04 (2006.01); C07D 471/10 (2006.01); C07D 487/04 (2006.01); C07D 491/107 (2006.01)
CPC C07D 209/08 (2013.01) [A61K 31/404 (2013.01); A61K 31/41 (2013.01); A61K 31/4155 (2013.01); A61K 31/422 (2013.01); A61K 31/426 (2013.01); A61K 31/427 (2013.01); A61K 31/433 (2013.01); A61K 31/435 (2013.01); A61K 31/437 (2013.01); A61K 31/4375 (2013.01); A61K 31/4439 (2013.01); A61K 31/454 (2013.01); A61K 31/4725 (2013.01); A61K 31/496 (2013.01); A61K 31/501 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/5377 (2013.01); A61K 31/541 (2013.01); A61K 31/551 (2013.01); A61K 45/06 (2013.01); A61P 31/20 (2018.01); A61P 35/00 (2018.01); C07D 277/62 (2013.01); C07D 401/10 (2013.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 403/10 (2013.01); C07D 403/12 (2013.01); C07D 403/14 (2013.01); C07D 405/12 (2013.01); C07D 405/14 (2013.01); C07D 409/12 (2013.01); C07D 413/10 (2013.01); C07D 417/10 (2013.01); C07D 417/12 (2013.01); C07D 471/04 (2013.01); C07D 471/08 (2013.01); C07D 471/10 (2013.01); C07D 487/04 (2013.01); C07D 487/08 (2013.01); C07D 491/107 (2013.01)] 10 Claims
 
1. A method of treating or ameliorating a disease or disorder caused by EBNA1 activity in a subject, wherein the disease or disorder caused by EBNA1 activity is selected from the group consisting of a cancer and infectious mononucleosis,
the method comprising administering to the subject a therapeutically effective amount of the compound 2-(1H-Indol-6-yl)-3-[4-(tetrahydro-pyran-4-yloxymethyl)-phenylethynyl]-benzoic acid, or a salt thereof.